Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Viramune
Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 34
HOS-088187 · Präparat HOS-083615
Zidovudine Zidovudine AUC 0.72 Zidovudine and Viramune can be
100-200 mg TID (0.60-0.96) co-administered without dose
Zidovudine Cmin ND adjustments
Zidovudine Cmax 0.70 (0.49-1.04)
Granulocytopenia is commonly
Nevirapine: Zidovudine had no associated with zidovudine.
effect on its pharmacokinetics. Therefore, patients who receive
nevirapine and zidovudine
concomitantly and especially
paediatric patients and patients
who receive higher zidovudine
doses or patients with poor bone
marrow reserve, in particular those
with advanced HIV disease, have
an increased risk of
granulocytopenia. In such patients
haematological parameters should
be carefully monitored.
NNRTIs
Efavirenz Efavirenz AUC 0.72 (0.66-0.86) It is not recommended to co-
600 mg QD Efavirenz Cmin 0.68 (0.65-0.81) administer efavirenz and Viramune
Efavirenz Cmax 0.88 (0.77-1.01) (see section 4.4), because of
additive toxicity and no benefit in
terms of efficacy over either
NNRTI alone (for results of 2NN
study, see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zidovudine (HOS-085837) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 2c3e817cc0f0f920657046a624b70120ad3862abf66eed3d4d8ef6820a85b2ba · Zeichen 3195–5408 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 11
HOS-108840 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of
Concentrations may be reduced reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg QD AUC: ↑ 32% Higher tenofovir concentrations
Cmax: ↔ could potentiate tenofovir
(equivalent to 245 mg Cmin: ↑ 51% associated adverse events,
tenofovir disoproxil) including renal disorders.
Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42%
Nevirapine, 200 mg BID Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51%
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir tablet Cmin: ↓ 45%
400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) fumarate (HOS-108845) efavirenz (HOS-087947) nevirapine (HOS-088064) etravirine (HOS-088088) abacavir (HOS-088077) zidovudine (HOS-085837) tenofovir disoproxil (HOS-108843)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 7e8d3e75ebcfb46fcb48f151d995ceb0e62959fafd1f9cc35b54c2dafa32e31e · Zeichen 2252–4083 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83
HOS-109075 · Präparat HOS-093083
Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of reduced
Concentrations may be reduced abacavir and zidovudine
due to increased glucuronidation concentrations is unknown.
by lopinavir/ritonavir.
Tenofovir disoproxil Tenofovir: No dose adjustment necessary.
fumarate (DF), 300 mg AUC: ↑ 32% Higher tenofovir concentrations
QD Cmax: ↔ could potentiate tenofovir
Cmin: ↑ 51% associated adverse events, including
(equivalent to 245 mg renal disorders.
tenofovir disoproxil) Lopinavir: ↔
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Efavirenz, 600 mg QD Lopinavir: See section 4.2 for Kaletra dosage
AUC: ↓ 20% recommendation or consider
Cmax: ↓ 13% alternative therapy.
Cmin: ↓ 42% Kaletra must not be administered
once daily in combination with
efavirenz.
Nevirapine, 200 mg Lopinavir: See section 4.2 for Kaletra dosage
BID AUC: ↓ 27% recommendation or consider
Cmax: ↓ 19% alternative therapy.
Cmin: ↓ 51% Kaletra must not be administered
once daily in combination with
nevirapine.
Etravirine Etravirine: No dose adjustment necessary
AUC: ↓ 35%
(Lopinavir/ritonavir Cmin: ↓ 45%
tablet 400/100 mg BID) Cmax: ↓ 30%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): zidovudine (HOS-085837) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) fumarate (HOS-108845) efavirenz (HOS-087947) nevirapine (HOS-088064) etravirine (HOS-088088) abacavir (HOS-088077)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c9296155c3ce5ef684722be8fb72dfceaf88100c0a3b2414e8bf3a028a9c0a3c · Zeichen 2392–4529 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-116511 · Präparat HOS-094447
53
Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs)
Didanosine didanosine AUC ↓ 9% PREZISTA co-administered with
400 mg once daily didanosine Cmin ND low dose ritonavir and didanosine
didanosine Cmax ↓ 16% can be used without dose
darunavir AUC ↔ adjustments.
darunavir Cmin ↔ Didanosine is to be administered
darunavir Cmax ↔ on an empty stomach, thus it
should be administered 1 hour
before or 2 hours after
PREZISTA/ritonavir given with
food.
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when PREZISTA
tenofovir Cmax ↑ 24% co-administered with low dose
#
darunavir AUC ↑ 21% ritonavir is given in combination
#
darunavir Cmin ↑ 24% with tenofovir disoproxil,
# particularly in patients with
darunavir Cmax ↑ 16%
underlying systemic or renal
(↑ tenofovir from effect on MDR-1
disease, or in patients taking
transport in the renal tubules)
nephrotoxic agents.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with PREZISTA
with low dose ritonavir.
Abacavir Not studied. Based on the different PREZISTA co-administered with
Emtricitabine elimination pathways of the other NRTIs low dose ritonavir can be used
Lamivudine zidovudine, emtricitabine, stavudine, with these NRTIs without dose
Stavudine lamivudine, that are primarily renally adjustment.
Zidovudine excreted, and abacavir for which
metabolism is not mediated by CYP450,
no interactions are expected for these
medicinal compounds and PREZISTA
co-administered with low dose ritonavir.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Etravirine etravirine AUC ↓ 37% PREZISTA co-administered with
100 mg twice daily etravirine Cmin ↓ 49% low dose ritonavir and etravirine
etravirine Cmax ↓ 32% 200 mg twice daily can be used
darunavir AUC ↑ 15% without dose adjustments.
darunavir Cmin ↔
darunavir Cmax ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) tenofovir alafenamide (HOS-110476) didanosine (HOS-085836) ritonavir (HOS-084521) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) emtricitabine (HOS-085840) efavirenz (HOS-087947) etravirine (HOS-088088)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f8ead3f953777de3c19f091bf055bc5528212e16095144f2b7b3940946af839d · Zeichen 6411–12375 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93–94
HOS-116603 · Präparat HOS-094447
93
Tenofovir disoproxil tenofovir AUC ↑ 22% Monitoring of renal function may
245 mg once daily‡ tenofovir Cmin ↑ 37% be indicated when boosted
tenofovir Cmax ↑ 24% PREZISTA is given in
#
darunavir AUC ↑ 21% combination with tenofovir
#
darunavir Cmin ↑ 24% disoproxil, particularly in patients
# with underlying systemic or renal
darunavir Cmax ↑ 16%
disease, or in patients taking
(↑ tenofovir from effect on MDR-1
nephrotoxic agents.
transport in the renal tubules)
PREZISTA co-administered with
cobicistat lowers the creatinine
clearance. Refer to section 4.4 if
creatinine clearance is used for
dose adjustment of tenofovir
disoproxil.
Emtricitabine/tenofovir Tenofovir alafenamide ↔ The recommended dose of
alafenamide Tenofovir ↑ emtricitabine/tenofovir
alafenamide is 200/10 mg once
daily when used with boosted
PREZISTA.
Abacavir Not studied. Based on the different Boosted PREZISTA can be used
Emtricitabine elimination pathways of the other NRTIs with these NRTIs without dose
Lamivudine zidovudine, emtricitabine, stavudine, adjustment.
Stavudine lamivudine, that are primarily renally
Zidovudine excreted, and abacavir for which PREZISTA co-administered with
metabolism is not mediated by CYP450, cobicistat lowers the creatinine
no interactions are expected for these clearance. Refer to section 4.4 if
medicinal compounds and boosted creatinine clearance is used for
PREZISTA. dose adjustment of emtricitabine or
lamivudine.
Non-nucleo(s/t)ide reverse transcriptase inhibitors (NNRTIs)
Efavirenz efavirenz AUC ↑ 21% Clinical monitoring for central
600 mg once daily efavirenz Cmin ↑ 17% nervous system toxicity associated
efavirenz Cmax ↑ 15% with increased exposure to
#
darunavir AUC ↓ 13% efavirenz may be indicated when
#
darunavir Cmin ↓ 31% PREZISTA co-administered with
# low dose ritonavir is given in
darunavir Cmax ↓ 15%
combination with efavirenz.
(↑ efavirenz from CYP3A inhibition)
(↓ darunavir from CYP3A induction)
Efavirenz in combination with
PREZISTA/ritonavir 800/100 mg
once daily may result in
sub-optimal darunavir Cmin. If
efavirenz is to be used in
combination with
PREZISTA/ritonavir, the
PREZISTA/ritonavir 600/100 mg
twice daily regimen should be used
(see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083) cobicistat (HOS-088111) creatinine (HOS-086273) emtricitabine (HOS-085840) tenofovir alafenamide (HOS-110476) abacavir (HOS-088077) lamivudine (HOS-085829) zidovudine (HOS-085837) stavudine (HOS-088080) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 08a2b9d3e388606555bc20885d7218a313fdbcadf305f03e98e87336cbf0f0e8 · Zeichen 10372–15436 im Abschnitt
Wechselwirkungen · Dovato
Dovato 50 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-142822 · Präparat HOS-098886
7
Nevirapine/Dolutegravir Dolutegravir The recommended dose of dolutegravir
(Not studied, a similar is 50 mg twice daily when
reduction in exposure as co-administered with nevirapine. As
observed with efavirenz is Dovato is a fixed-dose tablet, an
expected, due to additional 50 mg tablet of dolutegravir
induction) should be administered, approximately
12 hours after Dovato for the duration of
the nevirapine co-administration (a
separate formulation of dolutegravir is
available for this dose adjustment, see
section 4.2).
Rilpivirine/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 12%
Cmax 13%
Cτ 22%
Rilpivirine
Nucleoside reverse transcriptase inhibitors (NRTIs)
Tenofovir disoproxil Dolutegravir No dose adjustment is necessary when
AUC 1% Dovato is combined with tenofovir,
Cmax 3% didanosine, stavudine or zidovudine.
Cτ 8%
Tenofovir Dovato is not recommended for use in
combination with emtricitabine
containing products, since both
Emtricitabine, didanosine, Interaction not studied lamivudine (in Dovato) and
stavudine, tenofovir emtricitabine are cytidine analogues (i.e.
alafenamide, zidovudine risk for intracellular interactions), see
section 4.4.
Protease inhibitors
Atazanavir/Dolutegravir Dolutegravir No dose adjustment is necessary.
AUC 91%
Cmax 50%
C 180%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): emtricitabine (HOS-085840) protease (HOS-085623) atazanavir (HOS-086180) didanosine (HOS-085836) stavudine (HOS-088080) zidovudine (HOS-085837) nevirapine (HOS-088064) efavirenz (HOS-087947) rilpivirine (HOS-088090) tenofovir disoproxil (HOS-108843) tenofovir (HOS-088083)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T01:22:00Z · SHA-256 9ebb38c4be2b7abc7ba2934afb44e75aa1d6b86e46ecc069e568b333119de792 · Passage 3a54b7ec17f478707f317729fc54112d075d89e9ca126df050e9dd9dc88cd6d2 · Zeichen 7977–10650 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.